Spyre expands SPY003 license to all therapeutic uses, but faces dosing delays until 2030

Filed June 1, 2026 · Period ending May 29, 2026 · ~1 min read

Key Changes

• high

  SPY003 license field expanded from inflammatory bowel disease only to all therapeutic, prophylactic, palliative and diagnostic uses, significantly broadening commercial potential across multiple indications.

  Item 1.01 view on EDGAR →
• high

  Company cannot dose patients in clinical trials outside IBD until June 2028 for combination therapy or June 2030 for monotherapy, delaying ability to exploit expanded rights for 2-4 years.

  Item 1.01 view on EDGAR →
• medium

  Change of control provision accelerates timeline: if Spyre is acquired or completes material transaction, monotherapy dosing restriction terminates by June 2028 instead of 2030.

  Item 1.01 view on EDGAR →